Monitor the proxy statement filing and stockholder vote timeline. The deal is subject to HSR clearance and Nasdaq listing approval; any delays or regulatory issues could affect closing. Post-closing, watch for HRTX's deployment of proceeds and any strategic acquisition or investment.
Drugs in focus
HRTX drug pipeline →ZYNRELEF
● Neutral Named in this DEFA14A- Impact
- Phase
- Approved
- Time to market
- Already approved and commercialized (FDA approved May 2021). Under the CorMedix asset purchase agreement, ZYNRELEF will transfer to CorMedix upon deal close, expected Q1 2027.
- Next catalyst
- None dated
What to watchZYNRELEF is now part of the asset sale to CorMedix (CRMD), expected to close in Q1 2027. For HRTX shareholders, the stock is transitioning into a stub: Heron will retain CRMD shares, net operating loss carryforwards (~$2.3B), and earn-out rights. The next event is the shareholder vote and regulatory clearance for the sale. For investors tracking ZYNRELEF specifically, watch CorMedix's commercial execution post-close and any label expansion efforts under new ownership.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $0.3706entry
- T+1 · 7d ago +0.94%α +1.31% · $0.3741
- T+5 · 21h ago −23.29%α −21.59% · $0.2843
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Heron Therapeutics (HRTX) entered into a definitive Asset Purchase Agreement to sell substantially all of its assets to CorMedix Inc. for $145M in cash plus 14.6M CorMedix shares, contingent royalties on CINVANTI/SUSTOL sales above $25M in 2027-2029, and earn-out payments on ZYNRELEF sales in 2028. The deal requires HRTX stockholder approval, HSR clearance, and Nasdaq listing of the stock consideration. Supporting stockholders owning ~22% of HRTX shares have agreed to vote in favor. HRTX will retain its NOLs and the CorMedix shares received, and intends to remain publicly traded while evaluating strategic alternatives for the proceeds.
Key Financial Metrics
Key Facts
- Heron Therapeutics agreed to sell substantially all assets to CorMedix Inc.
- Total cash consideration is $145.0M, subject to working capital and closing cash adjustments
- Stock consideration: 14,583,333 shares of CorMedix common stock
- Contingent royalties: 5% of annual net sales of CINVANTI/SUSTOL above $25M in 2027, 2028, 2029
- Earn-out payments: $25M if ZYNRELEF 2028 net sales >= $65M; additional $30M if >= $95M
- HRTX retains its NOLs, the CorMedix shares, and cash on hand
- Supporting stockholders (~22% of shares) entered into voting agreements to approve the deal
- Transaction requires HRTX stockholder approval, HSR clearance, and Nasdaq listing of stock consideration
- HRTX intends to remain a publicly traded company and evaluate strategic alternatives for proceeds
- Rubric Capital Management will exchange $35M in convertible notes for CorMedix shares at closing
Financial Impact
Total consideration includes $145M base cash (subject to up to $10M adjustment), 14.6M CorMedix shares, plus potential royalties and up to $55M in earn-out payments
Risk Factors
- Transaction requires HRTX stockholder approval; failure to obtain would terminate the deal
- HSR waiting period and other antitrust approvals could delay or block closing
- Nasdaq listing approval for the stock consideration is a condition to closing
- HRTX will have no operating revenues post-closing and faces uncertainty in deploying proceeds
- Value of CorMedix stock consideration is subject to market fluctuations
- Earn-out and royalty payments are contingent on future product sales and may not materialize
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-452725 |
| Document: 0001193125-26-452725-index-headers.html | 0001193125-26-452725 |
| Document: 0001193125-26-452725-index.html | 0001193125-26-452725 |
| Document: 0001193125-26-452725.txt | 0001193125-26-452725 |
Track record
15 reports on HRTX
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +58.33% at T+20 after the May 11, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $0.3741 Now $0.2800 −25.15% settles Feb 8
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Viewing Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
- Nov 9, 20267d ago Press Release Mixed 7/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
- Aug 10, 202614w ago 8-K Bearish 7/10 No price data
- Aug 10, 202614w ago Press Release Bearish 7/10 Entry $0.3350 to $0.2847 Now $0.2800 +16.42% ▲ +15.01% +12.60% vs SPY
- Jun 25, 202620w ago 8-K Bearish 7/10 Entry $0.4300 to $0.2700 Now $0.2800 +34.88% ▲ +37.21% +43.31% vs SPY
- Jun 2, 202623w ago 8-K Bearish 7/10 Entry $0.4500 to $0.3321 Now $0.2800 +37.78% ▲ +26.20% +28.70% vs SPY
- May 11, 202627w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers